Christopher M Morris

List of Publications by Year
in descending order

214	14,443	23544	24961
papers	citations	58 h-index	109 g-index

218	218	218	18076
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Genetic evaluation of dementia with Lewy bodies implicates distinct disease subgroups. Brain, 2022, 145, 1757-1762.	3.7	17
2	Single-cell sequencing of human midbrain reveals glial activation and a Parkinson-specific neuronal state. Brain, 2022, 145, 964-978.	3.7	177
3	Blood mRNA Expression in Alzheimer's Disease and Dementia With Lewy Bodies. American Journal of Geriatric Psychiatry, 2022, 30, 964-975.	0.6	9
4	Neuropathological and biochemical investigation of Hereditary Ferritinopathy cases with ferritin light chain mutation: Prominent protein aggregation in the absence of major mitochondrial or oxidative stress. Neuropathology and Applied Neurobiology, 2021, 47, 26-42.	1.8	7
5	Feasibility of a randomised controlled trial to evaluate home-based virtual reality therapy in children with cerebral palsy. Disability and Rehabilitation, 2021, 43, 85-97.	0.9	27
6	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. Nature Genetics, 2021, 53, 294-303.	9.4	198
7	Gene Expression Imputation Across Multiple Tissue Types Provides Insight Into the Genetic Architecture of Frontotemporal Dementia and Its Clinical Subtypes. Biological Psychiatry, 2021, 89, 825-835.	0.7	10
8	RT-QuIC Using C-Terminally Truncated Î±-Synuclein Forms Detects Differences in Seeding Propensity of Different Brain Regions from Synucleinopathies. Biomolecules, 2021, 11, 820.	1.8	14
9	Healthy Parent Carers programme: mixed methods process evaluation and refinement of a health promotion intervention. BMJ Open, 2021, 11, e045570.	0.8	5
10	Altered ceramide metabolism is a feature in the extracellular vesicle-mediated spread of alpha-synuclein in Lewy body disorders. Acta Neuropathologica, 2021, 142, 961-984.	3.9	31
11	Genetic modifiers of risk and age at onset in GBA associated Parkinsonâ€™s disease and Lewy body dementia. Brain, 2020, 143, 234-248.	3.7	149
12	Mendelian randomization implies no direct causal association between leukocyte telomere length and amyotrophic lateral sclerosis. Scientific Reports, 2020, 10, 12184.	1.6	4
13	C9orf72, age at onset, and ancestry help discriminate behavioral from language variants in FTLD cohorts. Neurology, 2020, 95, e3288-e3302.	1.5	7
14	Prospective longitudinal evaluation of cytokines in mild cognitive impairment due to <scp>AD</scp> and Lewy body disease. International Journal of Geriatric Psychiatry, 2020, 35, 1250-1259.	1.3	14
15	Labelâ€Free Nanoimaging of Neuromelanin in the Brain by Soft Xâ€ray Spectromicroscopy. Angewandte Chemie - International Edition, 2020, 59, 11984-11991.	7.2	13
16	Labelâ€Free Nanoimaging of Neuromelanin in the Brain by Soft Xâ€ray Spectromicroscopy. Angewandte Chemie, 2020, 132, 12082-12089.	1.6	0
17	Investigating the presence of doubly phosphorylated Î±â€synuclein at tyrosine 125 and serine 129 in idiopathic Lewy body diseases. Brain Pathology, 2020, 30, 831-843.	2.1	15
18	C9orf72 intermediate repeats are associated with corticobasal degeneration, increased C9orf72 expression and disruption of autophagy. Acta Neuropathologica, 2019, 138, 795-811.	3.9	50

#	Article	IF	Citations
19	Neuropathological Changes in Dementia With Lewy Bodies and the Cingulate Island Sign. Journal of Neuropathology and Experimental Neurology, 2019, 78, 717-724.	0.9	15
20	MAPT p.V363I mutation. Neurology: Genetics, 2019, 5, e347.	0.9	10
21	Trichloroethylene and its metabolite TaClo lead to degeneration of substantia nigra dopaminergic neurones: Effects in wild type and human A30P mutant Î±-synuclein mice. Neuroscience Letters, 2019, 711, 134437.	1.0	19
22	Dementia with Lewy bodies: an update and outlook. Molecular Neurodegeneration, 2019, 14, 5.	4.4	203
23	A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimerâ€™s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. Acta Neuropathologica, 2019, 138, 237-250.	3.9	87
24	Inflammation in mild cognitive impairment due to Parkinson's disease, Lewy body disease, and Alzheimer's disease. International Journal of Geriatric Psychiatry, 2019, 34, 1244-1250.	1.3	31
25	Peripheral inflammation in mild cognitive impairment with possible and probable Lewy body disease and Alzheimerâ€™s disease. International Psychogeriatrics, 2019, 31, 551-560.	0.6	14
26	Assessment of APOE in atypical parkinsonism syndromes. Neurobiology of Disease, 2019, 127, 142-146.	2.1	21
27	Pathological Changes to the Subcortical Visual System and its Relationship to Visual Hallucinations in Dementia with Lewy Bodies. Neuroscience Bulletin, 2019, 35, 295-300.	1.5	15
28	Healthy Parent Carers peer-led group-based health promotion intervention for parent carers of disabled children: protocol for a feasibility study using a parallel group randomised controlled trial design. Pilot and Feasibility Studies, 2019, 5, 137.	0.5	2
29	Frequency and signature of somatic variants in 1461 human brain exomes. Genetics in Medicine, 2019, 21, 904-912.	1.1	20
30	Degeneration of dopaminergic circuitry influences depressive symptoms in Lewy body disorders. Brain Pathology, 2019, 29, 544-557.	2.1	33
31	Heterogeneity in Î±â€synuclein subtypes and their expression in cortical brain tissue lysates from Lewy body diseases and Alzheimer's disease. Neuropathology and Applied Neurobiology, 2019, 45, 597-608.	1.8	27
32	Molecular changes in the absence of severe pathology in the pulvinar in dementia with Lewy bodies. Movement Disorders, 2018, 33, 982-991.	2.2	24
33	Mitochondrial dysfunction within the synapses of substantia nigra neurons in Parkinsonâ€™s disease. Npj Parkinson's Disease, 2018, 4, 9.	2.5	92
34	Peripheral inflammation in prodromal Alzheimerâ€™s and Lewy body dementias. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 339-345.	0.9	141
35	Oligogenic genetic variation of neurodegenerative disease genes in 980 postmortem human brains. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 813-816.	0.9	17
36	Gene expression analysis reveals chronic low level exposure to the pesticide diazinon affects psychological disorders gene sets in the adult rat. Toxicology, 2018, 393, 90-101.	2.0	32

#	Article	IF	Citations
37	Regional levels of physiological Î±-synuclein are directly associated with Lewy body pathology. Acta Neuropathologica, 2018, 135, 153-154.	3.9	30
38	LRP10 in Î±-synucleinopathies. Lancet Neurology, The, 2018, 17, 1033-1034.	4.9	11
39	A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers. Brain, 2018, 141, 2895-2907.	3.7	39
40	Parent-to-parent support interventions for parents of babies cared for in a neonatal unitâ€"protocol of a systematic review of qualitative and quantitative evidence. Systematic Reviews, 2018, 7, 179.	2.5	12
41	High prevalence of focal and multi-focal somatic genetic variants in the human brain. Nature Communications, 2018, 9, 4257.	5.8	54
42	The human brainome: network analysis identifies HSPA2 as a novel Alzheimerâ€™s disease target. Brain, 2018, 141, 2721-2739.	3.7	31
43	Somatic variants in autosomal dominant genes are a rare cause of sporadic Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 1632-1639.	0.4	51
44	Specific patterns of neuronal loss in the pulvinar nucleus in dementia with lewy bodies. Movement Disorders, 2017, 32, 414-422.	2.2	32
45	Trichloroethylene-induced formic aciduria in the male C57 Bl/6 mouse. Toxicology, 2017, 378, 76-85.	2.0	8
46	Mitochondrial DNA point mutations and relative copy number in 1363 disease and control human brains. Acta Neuropathologica Communications, 2017, 5, 13.	2.4	83
47	Neuronal Loss and Î'-Synuclein Pathology in the Superior Colliculus and Its Relationship to Visual Hallucinations in Dementia with Lewy Bodies. American Journal of Geriatric Psychiatry, 2017, 25, 595-604.	0.6	29
48	SIRT1 ameliorates oxidative stress induced neural cell death and is down-regulated in Parkinsonâ€™s disease. BMC Neuroscience, 2017, 18, 46.	0.8	140
49	Interventions utilising contact with people with disabilities to improve children's attitudes towards disability: A systematic review and meta-analysis. Disability and Health Journal, 2017, 10, 11-22.	1.6	68
50	Genetic compendium of 1511 human brains available through the UK Medical Research Council Brain Banks Network Resource. Genome Research, 2017, 27, 165-173.	2.4	44
51	Mitochondrial DNA changes in pedunculopontine cholinergic neurons in Parkinson disease. Annals of Neurology, 2017, 82, 1016-1021.	2.8	45
52	Sirtuin-2 Protects Neural Cells from Oxidative Stress and Is Elevated in Neurodegeneration. Parkinson's Disease, 2017, 2017, 1-17.	0.6	34
53	Core Health Outcomes In Childhood Epilepsy (CHOICE): protocol for the selection of a core outcome set. Trials, 2017, 18, 572.	0.7	13
54	Telomerase Activity is Downregulated Early During Human Brain Development. Genes, 2016, 7, 27.	1.0	30

#	Article	IF	Citations
55	Changes to the lateral geniculate nucleus in A lzheimer's disease but not dementia with L ewy bodies. Neuropathology and Applied Neurobiology, 2016, 42, 366-376.	1.8	22
56	Analysis of primary visual cortex in dementia with Lewy bodies indicates GABAergic involvement associated with recurrent complex visual hallucinations. Acta Neuropathologica Communications, 2016, 4, 66.	2.4	58
57	Anatomic Connections of the Subgenual Cingulate Region. Neurosurgery, 2016, 79, 465-472.	0.6	34
58	Mechanism for the acute effects of organophosphate pesticides on the adult 5-HT system. Chemico-Biological Interactions, 2016, 245, 82-89.	1.7	32
59	Mitochondrial <scp>DNA</scp> Depletion in Respiratory Chainâ€“Deficient <scp>P</scp>arkinson Disease Neurons. Annals of Neurology, 2016, 79, 366-378.	2.8	189
60	Development of passive CLARITY and immunofluorescent labelling of multiple proteins in human cerebellum: understanding mechanisms of neurodegeneration in mitochondrial disease. Scientific Reports, 2016, 6, 26013.	1.6	43
61	Extended post-mortem delay times should not be viewed as a deterrent to the scientific investigation of human brain tissue: a study from the Brains for Dementia Research Network Neuropathology Study Group, UK. Acta Neuropathologica, 2016, 132, 753-755.	3.9	18
62	Exome sequencing in dementia with Lewy bodies. Translational Psychiatry, 2016, 6, e728-e728.	2.4	35
63	A Low Mortality, High Morbidity Reduced Intensity Status Epilepticus (RISE) Model of Epilepsy and Epileptogenesis in the Rat. PLoS ONE, 2016, 11, e0147265.	1.1	23
64	Rapid and equivalent systemic bioavailability of the antidotes HI-6 and dicobalt edetate via the intraosseous and intravenous routes. Emergency Medicine Journal, 2015, 32, 626-631.	0.4	8
65	Neural Differentiation Modulates the Vertebrate Brain Specific Splicing Program. PLoS ONE, 2015, 10, e0125998.	1.1	10
66	A Systematic Review of Generic Multidimensional Patient-Reported Outcome Measures for Children, Part I: Descriptive Characteristics. Value in Health, 2015, 18, 315-333.	0.1	56
67	Voxel-based analysis in neuroferritinopathy expands the phenotype and determines radiological correlates of disease severity. Journal of Neurology, 2015, 262, 2232-2240.	1.8	3
68	Diquat causes caspase-independent cell death in SH-SY5Y cells by production of ROS independently of mitochondria. Archives of Toxicology, 2015, 89, 1811-1825.	1.9	30
69	Selective loss of glucocerebrosidase activity in sporadic Parkinsonâ€™s disease and dementia with Lewy bodies. Molecular Neurodegeneration, 2015, 10, 15.	4.4	120
70	Low-level repeated exposure to diazinon and chlorpyrifos decrease anxiety-like behaviour in adult male rats as assessed by marble burying behaviour. NeuroToxicology, 2015, 50, 149-156.	1.4	41
71	Health outcomes for children with neurodisability: what do professionals regard as primary targets?. Archives of Disease in Childhood, 2014, 99, 927-932.	1.0	20
72	Intralobar fibres of the occipital lobe: A post mortem dissection study. Cortex, 2014, 56, 145-156.	1.1	54

#	Article	IF	Citations
73	White matter connections of the supplementary motor area in humans. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 1377-1385.	0.9	151
74	Pyroglutamylated amyloid-Î² is associated with hyperphosphorylated tau and severity of Alzheimerâ€™s disease. Acta Neuropathologica, 2014, 128, 67-79.	3.9	53
75	Frontotemporal dementia and its subtypes: a genome-wide association study. Lancet Neurology, The, 2014, 13, 686-699.	4.9	302
76	Acute Toxicity of Organophosphorus Compounds. , 2014, , 45-78.		6
77	Neuroferritinopathy. International Review of Neurobiology, 2013, 110, 91-123.	0.9	24
78	Mitochondrial Abnormality Associates with Type-Specific Neuronal Loss and Cell Morphology Changes in the Pedunculopontine Nucleus in Parkinson Disease. American Journal of Pathology, 2013, 183, 1826-1840.	1.9	53
79	Variation in tau isoform expression in different brain regions and disease states. Neurobiology of Aging, 2013, 34, 1922.e7-1922.e12.	1.5	49
80	Sex differences in effects of low level domoic acid exposure. NeuroToxicology, 2013, 34, 1-8.	1.4	17
81	Towards a definition of neurodisability: a Delphi survey. Developmental Medicine and Child Neurology, 2013, 55, 1103-1108.	1.1	113
82	A Multicenter Study of Glucocerebrosidase Mutations in Dementia With Lewy Bodies. JAMA Neurology, 2013, 70, 727.	4.5	374
83	Real-time monitoring of superoxide generation and cytotoxicity in neuroblastoma mitochondria induced by 1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline. Redox Report, 2012, 17, 108-114.	1.4	10
84	Raymond de Vieussens and his contribution to the study of white matter anatomy. Journal of Neurosurgery, 2012, 117, 1070-1075.	0.9	10
85	Relationship Between Mitochondria and Î±-Synuclein. Archives of Neurology, 2012, 69, 385.	4.9	43
86	Glucocerebrosidase Mutations alter the endoplasmic reticulum and lysosomes in Lewy body disease. Journal of Neurochemistry, 2012, 123, 298-309.	2.1	58
87	Transferrin and HFE genes interact in Alzheimer's disease risk: the Epistasis Project. Neurobiology of Aging, 2012, 33, 202.e1-202.e13.	1.5	51
88	FUS and TDP43 genetic variability in FTD and CBS. Neurobiology of Aging, 2012, 33, 1016.e9-1016.e17.	1.5	69
89	Synaptic Protein Alterations in Parkinsonâ€™s Disease. Molecular Neurobiology, 2012, 45, 126-143.	1.9	27
90	Morphometric Analysis of Neuronal and Glial Cell Pathology in the Caudate Nucleus in Late-Life Depression. American Journal of Geriatric Psychiatry, 2011, 19, 132-141.	0.6	36

#	Article	IF	Citations
91	Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nature Genetics, 2011, 43, 699-705.	9.4	502
92	NOS3 gene rs1799983 polymorphism and incident dementia in elderly stroke survivors. Neurobiology of Aging, 2011, 32, 554.e1-554.e6.	1.5	15
93	Any old iron?. Brain, 2011, 134, 924-927.	3.7	4
94	A morphometric examination of neuronal and glial cell pathology in the orbitofrontal cortex in late-life depression. International Psychogeriatrics, 2011, 23, 132-140.	0.6	45
95	The immunhistochemical examination of GABAergic interneuron markers in the dorsolateral prefrontal cortex of patients with late-life depression. International Psychogeriatrics, 2011, 23, 644-653.	0.6	32
96	Examination of glucose transporterâ€1, transforming growth factorâ€Î² and neuroglobin immunoreactivity in the orbitofrontal cortex in lateâ€life depression. Psychiatry and Clinical Neurosciences, 2011, 65, 158-164.	1.0	5
97	Cellular pathology within the anterior cingulate cortex of patients with late-life depression: A morphometric study. Psychiatry Research - Neuroimaging, 2011, 194, 184-189.	0.9	23
98	Expression analysis of dopaminergic neurons in Parkinsonâ€™s disease and aging links transcriptional dysregulation of energy metabolism to cell death. Acta Neuropathologica, 2011, 122, 75-86.	3.9	127
99	Singleâ€cell expression profiling of dopaminergic neurons combined with association analysis identifies pyridoxal kinase as Parkinson's disease gene. Annals of Neurology, 2009, 66, 792-798.	2.8	49
100	BuChEâ€K and APOE Ïµ4 allele frequencies in Lewy body dementias, and influence of genotype and hyperhomocysteinemia on cognitive decline. Movement Disorders, 2009, 24, 392-400.	2.2	39
101	The low abundance of clonally expanded mitochondrial DNA point mutations in aged substantia nigra neurons. Aging Cell, 2009, 8, 496-498.	3.0	26
102	Morphometric analysis of neuronal and glial cell pathology in the dorsolateral prefrontal cortex in late-life depression. British Journal of Psychiatry, 2009, 195, 163-169.	1.7	59
103	Decreased Fractalkine and Increased IP-10 Expression in Aged Brain of APPswe Transgenic Mice. Neurochemical Research, 2008, 33, 1085-1089.	1.6	74
104	Nature of Mitochondrial DNA Deletions in Substantia Nigra Neurons. American Journal of Human Genetics, 2008, 82, 228-235.	2.6	123
105	Common genetic variation within the Low-Density Lipoprotein Receptor-Related Protein 6 and late-onset Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 9434-9439.	3.3	252
106	Hereditary multi-infarct dementia of the Swedish type is a novel disorder different from NOTCH3 causing CADASIL. Brain, 2007, 130, 357-367.	3.7	51
107	Soluble cell adhesion molecules in late-life depression. International Psychogeriatrics, 2007, 19, 914-920.	0.6	19
108	Preliminary observation of elevated levels of nanocrystalline iron oxide in the basal ganglia of neuroferritinopathy patients. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2007, 1772, 21-25.	1.8	66

#	Article	IF	Citations
109	The MAPT H1c risk haplotype is associated with increased expression of tau and especially of 4 repeat containing transcripts. Neurobiology of Disease, 2007, 25, 561-570.	2.1	231
110	A Scan of Chromosome 10 Identifies a Novel Locus Showing Strong Association with Late-Onset Alzheimer Disease. American Journal of Human Genetics, 2006, 78, 78-88.	2.6	157
111	Quantification of Alzheimer pathology in ageing and dementia: age-related accumulation of amyloid-beta(42) peptide in vascular dementia. Neuropathology and Applied Neurobiology, 2006, 32, 103-118.	1.8	131
112	High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nature Genetics, 2006, 38, 515-517.	9.4	1,363
113	Does the mitochondrial genome play a role in the etiology of Alzheimerâ€™s disease?. Human Genetics, 2006, 119, 241-254.	1.8	102
114	Ubiquilin 1 polymorphisms are not associated with late-onset Alzheimer's disease. Annals of Neurology, 2006, 59, 21-26.	2.8	37
115	Genetic Variability in CHMP2B and Frontotemporal Dementia. Neurodegenerative Diseases, 2006, 3, 129-133.	0.8	47
116	Apolipoprotein Â3 allele is associated with persistent hepatitis C virus infection. Gut, 2006, 55, 715-718.	6.1	81
117	Familial neurocardiogenic (vasovagal) syncope. American Journal of Medical Genetics, Part A, 2005, 133A, 176-179.	0.7	22
118	Association studies between risk for late-onset Alzheimer's disease and variants in insulin degrading enzyme. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2005, 136B, 62-68.	1.1	35
119	APOA1 polymorphism influences risk for early-onset nonfamiliar AD. Annals of Neurology, 2005, 58, 436-441.	2.8	68
120	Screening of the regulatory and coding regions of vascular endothelial growth factor in amyotrophic lateral sclerosis. Neurogenetics, 2005, 6, 101-104.	0.7	15
121	Comparative proteomic analysis using samples obtained with laser microdissection and saturation dye labelling. Proteomics, 2005, 5, 3851-3858.	1.3	55
122	Linkage disequilibrium fine mapping and haplotype association analysis of the tau gene in progressive supranuclear palsy and corticobasal degeneration. Journal of Medical Genetics, 2005, 42, 837-846.	1.5	225
123	Increase in Interleukin-1Î² in Late-Life Depression. American Journal of Psychiatry, 2005, 162, 175-177.	4.0	269
124	The K Variant of the Butyrylcholinesterase Gene Is Associated with Reduced Phosphorylation of Tau in Dementia Patients. Dementia and Geriatric Cognitive Disorders, 2005, 19, 357-360.	0.7	22
125	Impact of Hypertension and Apolipoprotein E4 on Poststroke Cognition in Subjects >75 Years of Age. Stroke, 2005, 36, 1864-1868.	1.0	29
126	Angiotensin converting enzyme insertion/deletion polymorphisms in vasovagal syncope. Europace, 2005, 7, 396-399.	0.7	15

#	Article	IF	Citations
127	The H1c haplotype at the MAPT locus is associated with Alzheimer's disease. Human Molecular Genetics, 2005, 14, 2399-2404.	1.4	205
128	Novel presenilin 1 mutation with profound neurofibrillary pathology in an indigenous Southern African family with early-onset Alzheimer's disease. Brain, 2004, 127, 133-142.	3.7	42
129	Dementia with Lewy bodies: no association of polymorphisms in the human synphilin gene. Neurogenetics, 2004, 5, 251-252.	0.7	3
130	High throughput approaches in neuroscience. International Journal of Developmental Neuroscience, 2004, 22, 515-522.	0.7	13
131	Chronic glial activation, neurodegeneration, and APP immunoreactive deposits following acute administration of double-stranded RNA. Glia, 2003, 44, 1-12.	2.5	53
132	Cholinesterase inhibitors in the treatment of dementia. International Journal of Geriatric Psychiatry, 2003, 18, 458-459.	1.3	2
133	Polymorphism in the human DJ-1 gene is not associated with sporadic dementia with Lewy bodies or Parkinson's disease. Neuroscience Letters, 2003, 352, 151-151.	1.0	0
134	Polymorphism in the human DJ-1 gene is not associated with sporadic dementia with Lewy bodies or Parkinson's disease. Neuroscience Letters, 2003, 352, 151-153.	1.0	34
135	Regulation of attention and response to therapy in dementia by butyrylcholinesterase. Pharmacogenetics and Genomics, 2003, 13, 231-239.	5.7	85
136	A15-3 Angiotensin-converting enzyme insertion/deletion polymorphism and tilt diagnosed vasovagal syncope. Europace, 2003, 4, B23-B23.	0.7	1
137	Dementia with Lewy bodies. Seminars in Clinical Neuropsychiatry, 2003, 8, 46-57.	1.9	124
138	Clinical and Neuropathological Correlates of Apolipoprotein E Genotype in Dementia with Lewy Bodies. Dementia and Geriatric Cognitive Disorders, 2002, 14, 167-175.	0.7	57
139	Selective Nicotinic Receptor Consequences in APPSWE Transgenic Mice. Molecular and Cellular Neurosciences, 2002, 20, 354-365.	1.0	60
140	Neuroferritinopathy: A Window on the Role of Iron in Neurodegeneration. Blood Cells, Molecules, and Diseases, 2002, 29, 522-531.	0.6	67
141	Transferrin gene polymorphism in Alzheimer's disease and dementia with Lewy bodies in humans. Neuroscience Letters, 2002, 317, 13-16.	1.0	31
142	The tau locus is not significantly associated with pathologically confirmed sporadic Parkinson's disease. Neuroscience Letters, 2002, 330, 201-203.	1.0	39
143	Up-regulation of the inflammatory cytokines IFN-Î³ and IL-12 and down-regulation of IL-4 in cerebral cortex regions of APPSWE transgenic mice. Journal of Neuroimmunology, 2002, 126, 50-57.	1.1	150
144	Nitric oxide synthase gene polymorphisms in Alzheimer's disease and dementia with Lewy bodies. Neuroscience Letters, 2001, 303, 33-36.	1.0	38

#	Article	IF	Citations
145	No pathogenic mutations in the synphilin-1 gene in Parkinson's disease. Neuroscience Letters, 2001, 307, 125-127.	1.0	18
146	Is apolipoprotein e4 associated with cognitive decline in depression?. International Journal of Geriatric Psychiatry, 2001, 16, 436-437.	1.3	8
147	The progression of cognitive impairment in dementia with Lewy bodies, vascular dementia and Alzheimer's disease. International Journal of Geriatric Psychiatry, 2001, 16, 499-503.	1.3	106
148	Parkinson's disease is not associated with the combined ?-synuclein/apolipoprotein E susceptibility genotype. Annals of Neurology, 2001, 49, 665-668.	2.8	66
149	Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. Nature Genetics, 2001, 28, 350-354.	9.4	533
150	Neuritogenic-Neurotoxic Effects of Membrane-Associated Forms ofAmyloid Precursor Prot ein. Dementia and Geriatric Cognitive Disorders, 2001, 12, 40-51.	0.7	4
151	The CCTTT polymorphism in the NOS2A gene is associated with dementia with Lewy bodies. NeuroReport, 2000, 11, 297-299.	0.6	29
152	Non-Alzheimer dementias. Current Opinion in Psychiatry, 2000, 13, 409-414.	3.1	1
153	Distribution of Amyloid beta42 in Relation to the Cerebral Microvasculature in an Elderly Cohort with Alzheimer's Disease. Annals of the New York Academy of Sciences, 2000, 903, 83-88.	1.8	27
154	Hereditary Vascular Dementia Linked to Notch 3 Mutations: CADASIL in British Families. Annals of the New York Academy of Sciences, 2000, 903, 293-298.	1.8	28
155	Brain oestradiol and testosterone levels in Alzheimer's disease. Neuroscience Letters, 2000, 286, 1-4.	1.0	41
156	Brain matrix metalloproteinase 1 levels are elevated in Alzheimer's disease. Neuroscience Letters, 2000, 291, 201-203.	1.0	80
157	Aberrant Splicing in the Presenilin-1 Intron 4 Mutation Causes Presenile Alzheimer's Disease by Increased AÂ42 Secretion. Human Molecular Genetics, 1999, 8, 1529-1540.	1.4	84
158	Frequency of HLA-A and B alleles in early and late-onset Alzheimer's disease. Neuroscience Letters, 1999, 262, 140-142.	1.0	19
159	Risk for Alzheimer's disease in older late-onset cases is associated with HLA-DRB1*03. Neuroscience Letters, 1999, 275, 137-140.	1.0	25
160	Apolipoprotein E Ïµ4 Allele, Temporal Lobe Atrophy, and White Matter Lesions in Late-Life Dementias. Archives of Neurology, 1999, 56, 961.	4.9	82
161	Î±2-Macroglobulin polymorphisms in AlzheimerÊ¼s disease and dementia with Lewy bodies. NeuroReport, 1999, 10, 1507-1510.	0.6	29
162	LRP gene and late-onset Alzheimer's disease. Lancet, The, 1998, 352, 239-240.	6.3	23

#	Article	IF	Citations
163	Butyrylcholinesterase K: an association with dementia with Lewy bodies. Lancet, The, 1998, 351, 1818.	6.3	15
164	Dopamine and nicotinic receptor binding and the levels of dopamine and homovanillic acid in human brain related to tobacco use. Neuroscience, 1998, 87, 63-78.	1.1	127
165	Neuroblastoma and Alzheimerâ€™s Disease Brain Cells Contain Aromatase Activity. Steroids, 1998, 63, 263-267.	0.8	44
166	Diagnosis of Mitochondrial Disease: Assessment of Mitochondrial DNA Heteroplasmy in Blood. Biochemical and Biophysical Research Communications, 1998, 251, 883-887.	1.0	41
167	No association between the K variant of the butyrylcholinesterase gene and pathologically confirmed Alzheimer's disease. Human Molecular Genetics, 1998, 7, 937-939.	1.4	58
168	Lack of association between the dopamine D2 receptor gene allele DRD2*A1 and cigarette smoking in a United Kingdom population. Pharmacogenetics and Genomics, 1998, 8, 125-128.	5.7	66
169	Dementia with Lewy Bodies. A Distinct Nonâ€Alzheimer Dementia Syndrome?. Brain Pathology, 1998, 8, 299-324.	2.1	96
170	D2 dopamine receptor gene (DRD2) TaqI A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics and Genomics, 1997, 7, 479-484.	5.7	518
171	HLA-DR antigens associated with major genetic risk for late-onset AlzheimerÊ¼s disease. NeuroReport, 1997, 8, 1467-1469.	0.6	56
172	No association between a polymorphism in the presenilin 1 gene and dementia with Lewy bodies. NeuroReport, 1997, 8, 3637-3639.	0.6	10
173	Presenilin polymorphisms in Alzheimer's disease. Lancet, The, 1997, 350, 958-959.	6.3	12
174	No association between an intronic polymorphism in the presenilin-1 gene and Alzheimer's disease. Neuroscience Letters, 1997, 234, 19-22.	1.0	17
175	The Nicotinic Cholinergic System and ÃŸ-Amyloidosis. , 1997, , 275-279.		2
176	Apolipoprotein E Genotype and Alzheimer's Disease in an Elderly Norwegian Cohort. Experimental Neurology, 1996, 5, 43-47.	1.7	7
177	Apolipoprotein E genotyping in Alzheimer's disease. Lancet, The, 1996, 347, 1775-1776.	6.3	23
178	Effect of aluminium on expression and processing of amyloid precursor protein. , 1996, 46, 395-403.		21
179	Effect of apolipoprotein E genotype on Alzheimer's disease neuropathology in a cohort of elderly Norwegians. Neuroscience Letters, 1995, 201, 45-48.	1.0	38
180	Effects of Apolipoprotein E Genotype on Cortical Neuropathology in Senile Dementia of the Lewy Body and Alzheimer's Disease. Experimental Neurology, 1995, 4, 443-448.	1.7	34

#	Article	IF	Citations
181	The role of the cholinergic system in the development of the human cerebellum. Developmental Brain Research, 1995, 90, 159-167.	2.1	64
182	Alteration in nicotine binding sites in Parkinson's disease, Lewy body dementia and Alzheimer's disease: Possible index of early neuropathology. Neuroscience, 1995, 64, 385-395.	1.1	396
183	Transferrin receptors in the Parkinsonian midbrain. Neuropathology and Applied Neurobiology, 1994, 20, 468-472.	1.8	49
184	Distribution of Nicotinic Receptors in the Human Hippocampus and Thalamus. European Journal of Neuroscience, 1994, 6, 1596-1604.	1.2	130
185	Transferrin receptors in the normal human hippocampus and in Alzheimer's disease. Neuropathology and Applied Neurobiology, 1994, 20, 473-477.	1.8	28
186	Protective effect of apoE ∈2 in Alzheimer's disease. Lancet, The, 1994, 344, 473-474.	6.3	76
187	Apolipoprotein E genes in Lewy body and Parkinson's disease. Lancet, The, 1994, 343, 1565.	6.3	83
188	Distribution of neuronal nicotinic receptor subunits in human brain. Neurochemistry International, 1994, 25, 69-71.	1.9	50
189	Autoradiographic comparison of cholinergic and other transmitter receptors in the normal human hippocampus. Hippocampus, 1993, 3, 307-315.	0.9	57
190	Iron uptake in the brain of the myelin-deficient rat. Neuroscience Letters, 1993, 154, 187-190.	1.0	25
191	Evidence for the localization of haemopexin immunoreactivity in neurones in the human brain. Neuroscience Letters, 1993, 149, 141-144.	1.0	49
192	Cholinergic Transmitter and Neurotrophic Activities in Lewy Body Dementia. Alzheimer Disease and Associated Disorders, 1993, 7, 69-79.	0.6	219
193	Hippocampal p75 Nerve Growth Factor Receptor Immunoreactivity in Development, Normal Aging and Senescence. Cells Tissues Organs, 1993, 147, 216-222.	1.3	12
194	Histochemical Distribution of Non-Haem Iron in the Human Brain. Cells Tissues Organs, 1992, 144, 235-257.	1.3	193
195	Immunocytochemical Localisation of Transferrin in the Human Brain. Cells Tissues Organs, 1992, 143, 14-18.	1.3	36
196	The imaging and quantification of aluminium in the human brain using dynamic secondary ion mass spectrometry (SIMS). Biology of the Cell, 1992, 74, 109-118.	0.7	29
197	Hippocampal nerve growth factor receptor immunoreactivity in patients with Alzheimer's and Parkinson's disease. Neuroscience Letters, 1992, 143, 101-104.	1.0	26
198	Distribution of transferrin receptors in relation to cytochrome oxidase activity in the human spinal cord, lower brainstem and cerebellum. Journal of the Neurological Sciences, 1992, 111, 158-172.	0.3	31

#	Article	IF	Citations
199	Nerve Growth Factor Receptor-like Immunoreactivity in the Human Spinal Cord. Cells Tissues Organs, 1992, 144, 348-353.	1.3	4
200	Uptake and Distribution of Iron and Transferrin in the Adult Rat Brain. Journal of Neurochemistry, 1992, 59, 300-306.	2.1	129
201	Brain iron homeostasis. Journal of Inorganic Biochemistry, 1992, 47, 257-265.	1.5	84
202	Distribution of nerve growth factor receptor immunoreactivity in the human hippocampus. Neuroscience Letters, 1991, 121, 178-182.	1.0	24
203	Transferrin-gallium binding in Alzheimer's disease. Lancet, The, 1991, 338, 1394-1396.	6.3	6
204	Laterality and 5HT2 receptors in human brain. Psychiatry Research, 1991, 36, 169-174.	1.7	4
205	Cortical serotonin-S2 receptor binding in Lewy body dementia, Alzheimer's and Parkinson's diseases. Journal of the Neurological Sciences, 1991, 106, 50-55.	0.3	95
206	Brain transferrin receptors and the distribution of cytochrome oxidase. Biochemical Society Transactions, 1990, 18, 647-648.	1.6	11
207	Nerve growth factor receptor-positive fibre pathways in the human neocortex. Biochemical Society Transactions, 1990, 18, 661-663.	1.6	0
208	Gallium-67 as a Potential Marker for Aluminium Transport in Rat Brain: Implications for Alzheimer's Disease. Journal of Neurochemistry, 1990, 55, 251-259.	2.1	54
209	Gallium-transferrin binding in Alzheimer disease. Lancet, The, 1990, 335, 1348-1350.	6.3	3
210	Comparison of the regional distribution of transferrin receptors and aluminium in the forebrain of chronic renal dialysis patients. Journal of the Neurological Sciences, 1989, 94, 295-306.	0.3	66
211	Interaction between metal ions and neuroleptics. Biochemical Society Transactions, 1989, 17, 218-218.	1.6	0
212	Comparison of the regional distribution of transferrin receptors and aluminium in the forebrain of chronic renal dialysis patients. Biochemical Society Transactions, 1989, 17, 669-670.	1.6	3
213	The role of transferrin in the uptake of aluminium and manganese by the IMR 32 neuroblastoma cell line. Biochemical Society Transactions, 1987, 15, 498-498.	1.6	25
214	Transferrin and transferrin receptors in normal brain and in Alzheimer's disease. Biochemical Society Transactions, 1987, 15, 891-892.	1.6	17